Juno Therapeutics Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.

Juno Therapeutics Inc. (NASDAQ:JUNO)’s Financial Overview

Juno Therapeutics Inc. (NASDAQ:JUNO) declined -5.11% yesterday to close its trading session at $20.05. The company has 1 year Price Target of $35.5. Juno Therapeutics Inc. has 52-Week high of $56.64 and 52-Week Low of $19.41. The stock touched its 52-Week High on Dec 3, 2015 and 52-Week Low on Nov 23, 2016. The stock traded with the volume of 2.78 Million shares yesterday. The firm shows the market capitalization of $2.12 Billion.

Juno Therapeutics Inc. (NASDAQ:JUNO) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.57/share against the analyst consensus estimate of $-0.55/share. The difference between the actual and expected EPS is $-0.02 a share with a surprise factor of -3.6%.

The firm is trading with SMA20 of -26.07 Percent, SMA50 of -28.41 Percent and SMA200 of -42.28 percent. Juno Therapeutics Inc. has P/S value of 34.02 while its P/B value stands at 1.83. Similarly, the company has Return on Assets of -19 percent, Return on Equity of -24 percent and Return on Investment of -20.3 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

Many brokerage firms are involved in issuing their ratings on Juno Therapeutics Inc. (NASDAQ:JUNO). On 25-Nov-16 SunTrust Downgrade Juno Therapeutics Inc. Stock  to Hold. Another firm also rated the stock on 23-Nov-16 where FBR & Co. Downgrade the stock to Mkt Perform.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 12 analysts offering 12-month price forecasts for Juno Therapeutics Inc have a median target of 45.00, with a high estimate of 61.00 and a low estimate of 23.00. The median estimate represents a +124.44% increase from the last price of 20.05.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Overseas Shipholding Group Inc. (NYSE:OSG)

Overseas Shipholding Group, Inc. is a tanker company. The company provides energy transportation services for crude oil and petroleum products primarily in the U.S. and International markets. Overseas Shipholding Group, Inc. is headquartered in New York City.

Overseas Shipholding Group Inc. (NYSE:OSG)’s Financial Outlook

There is no forecast data available.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Overseas Shipholding Group Inc. has a Consensus Recommendation of NA. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -2.77% and closed its last trading session at $7.73. The company has the market capitalization of $542.65 Million. The stock has 52-week high of $13.15 and 52-Week low of $7.71. The firm touched its 52-Week high on Jul 25, 2016 and 52-Week low on Nov 29, 2016. The company has volume of 1.15 Million shares. The company has a total of 70.2 Million shares outstanding.

Overseas Shipholding Group Inc. (NYSE:OSG) in the last quarter reported its actual EPS of $-0.03/share where the analyst estimated EPS was $0.06/share. The difference between the actual and Estimated EPS is $-0.09. This shows a surprise factor of -150 percent.

The company has YTD performance of -29.08 percent. Beta for Overseas Shipholding Group Inc. stands at 0 while its ATR (average true range) is 0.36. The company has Weekly Volatility of 3.65%% and Monthly Volatility of 4.54%%.

Overseas Shipholding Group Inc. has distance from 20-day Simple Moving Average (SMA20) of -7.25%, Distance from 50-Day Simple Moving Average of -18.48 percent and Distance from 200-Day Simple Moving Average of -27.14%.

The Company currently has ROA (Return on Assets) of -0.3 percent, Return on Equity (ROE) of -0.6 Percent and Return on Investment (ROI) of 14.8% with Gross margin of 50.7 percent and Operating & Profit margin of 13.4% and -1% respectively.